Antimicrobial prophylaxis can decrease the incidence of postoperative surgical site infection after some procedures. Since the last Medical Letter article on this subject, consensus guidelines have been published.1 Recommendations for prophylaxis in specific surgical procedures are listed in Table 1.
CHOICE OF AGENT — Antimicrobial prophylaxis for surgery should be directed against the most likely infecting organisms, but it does not need to eradicate every potential pathogen to be effective. Cefazolin (Ancef, and others), a first-generation cephalosporin active against many staphylococci and streptococci, can be used for most procedures.
The second-generation cephalosporins cefoxitin (Mefoxin, and others) and cefotetan (Cefotan, and others) are recommended for procedures that involve exposure to bowel flora, including Escherichia coli and Bacteroides fragilis, but...
- Treatment of Lyme Disease
- Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
- Odefsey - Another NNRTI Combination for HIV
- BioThrax and Anthrasil for Anthrax
- In Brief: Two Drugs for Soft-Tissue Sarcoma (online only)
The FDA has approved a once-daily, extended-release chewable tablet formulation of methylphenidate (QuilliChew ER – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first long-acting chewable formulation of the drug to be marketed in the US. Immediate-release chewable methylphenidate tablets (Methylin, and generics) have been available since 2003.1